Cdk inhibitor BAI | CAS#N/A | cancer therapeutic agent

MedKoo Cat#: 130189 | Name: Cdk inhibitor BAI

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cdk inhibitor BAI is a cancer therapeutic agent with anti-proliferative effects that plays a key role in FTI-mediated apoptosis in human renal carcinoma cells, as well as the treatment of head and neck cancers. For the treatment of renal carcinoma, by synergizing with FTI, BAI activates DEVDase, cleaves PARP, and leads to the degradation of anti-apoptotic proteins in Caki cells. BAI was also found to inhibit the expression of ICAM-1 and VCAM-1 which in turn leads to the inhibition of cell adhesion, in part due to the down-regulation of the activity of NF-κB.

Chemical Structure

Cdk inhibitor BAI

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 130189

Name: Cdk inhibitor BAI

CAS#: N/A

Chemical Formula: C24H22N4O3S

Exact Mass: 446.1413

Molecular Weight: 446.53

Elemental Analysis: C, 64.56; H, 4.97; N, 12.55; O, 10.75; S, 7.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Cdk inhibitor BAI

IUPAC/Chemical Name

2-([1,1'-biphenyl]-4-yl)-N-(5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl)acetamide

InChi Key

ACNJMIYZGUUYIE-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H22N4O3S/c29-23(15-17-7-9-19(10-8-17)18-5-2-1-3-6-18)25-24-21-16-20(11-12-22(21)26-27-24)28-13-4-14-32(28,30)31/h1-3,5-12,16H,4,13-15H2,(H2,25,26,27,29)

SMILES Code

O=C(NC1=NNC2=C1C=C(N(CCC3)S3(=O)=O)C=C2)CC4=CC=C(C5=CC=CC=C5)C=C4

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 446.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1. Jang JH, Cho YC, Kim KH, Lee KS, Lee J, Kim DE, Park JS, Jang BC, Kim S, Kwon TK, Park JW. BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L). Int J Oncol. 2014 Oct;45(4):1680-90. doi: 10.3892/ijo.2014.2534. Epub 2014 Jul 4. PMID: 24993441. 2. Shin HC, Song DW, Baek WK, Lee SR, Kwon TK, Lee J, Park SH, Jang BC, Park JW. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor. Chemotherapy. 2009;55(5):353-62. doi: 10.1159/000232450. Epub 2009 Aug 5. PMID: 19657189. 3. Oh JH, Park EJ, Park JW, Lee J, Lee SH, Kwon TK. A novel cyclin-dependent kinase inhibitor down-regulates tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules by inhibition of NF-kappaB activation in human pulmonary epithelial cells. Int Immunopharmacol. 2010 May;10(5):572-9. doi: 10.1016/j.intimp.2010.02.004. Epub 2010 Feb 13. PMID: 20156602.